Cite
Exposure to Rifampicin Is Strongly Reduced in Patients with Tuberculosis and Type 2 Diabetes.
MLA
Nijland, Hanneke M. J., et al. “Exposure to Rifampicin Is Strongly Reduced in Patients with Tuberculosis and Type 2 Diabetes.” Clinical Infectious Diseases, vol. 43, no. 7, Oct. 2006, pp. 848–54. EBSCOhost, https://doi.org/10.1086/507543.
APA
Nijland, H. M. J., Ruslami, R., Stalenhoef, J. E., Nelwan, E. J., Alisjahbana, B., Nelwan, R. H. H., van der Ven, A. J. A. M., Danusantoso, H., Aarnoutse, R. E., & van Crevel, R. (2006). Exposure to Rifampicin Is Strongly Reduced in Patients with Tuberculosis and Type 2 Diabetes. Clinical Infectious Diseases, 43(7), 848–854. https://doi.org/10.1086/507543
Chicago
Nijland, Hanneke M. J., Rovina Ruslami, Janneke E. Stalenhoef, Erni J. Nelwan, Bachti Alisjahbana, Ron H. H. Nelwan, Andre J. A. M. van der Ven, Halim Danusantoso, Rob E. Aarnoutse, and Reinout van Crevel. 2006. “Exposure to Rifampicin Is Strongly Reduced in Patients with Tuberculosis and Type 2 Diabetes.” Clinical Infectious Diseases 43 (7): 848–54. doi:10.1086/507543.